Acute GVHD (aGVHD) refractory to initial treatment with corticosteroids is associated with high rates of morbidity and mortality. [1] [2] [3] [4] [5] Although several different agents have been proposed as therapy for steroid-refractory aGVHD, there remains no consensus as to optimal management following failure of corticosteroids. At our institution, steroid-refractory aGVHD is routinely treated with antithymocyte globulin (ATG), etanercept ± mycophenolate mofetil. 5 Although this approach is able to salvage a significant proportion of patients, prognosis is historically dismal in those patients refractory to second-line therapy. Given the reports of steroid-refractory aGVHD responding to alemtuzumab, [1] [2] [3] [4] 6, 7 we have incorporated this agent as third-line therapy in patients failing the above strategies. Herein, we report the outcome of 13 patients with steroid and ATG/etanercept-refractory aGVHD treated with alemtuzumab as third-line therapy at our institution.
Patients were identified retrospectively from an institutional database and clinical outcomes determined by review of medical records. GVHD diagnosis was biopsy proven and clinically graded according to the Gluksberg criteria. 8 Steroid-refractory aGVHD was defined as progressive GVHD after 3 days of methylprednisolone X2 mg/kg/ day, no change in GVHD grade after 7 days of methylprednisolone, ocomplete response (CR) after 14 days of methylprednisolone or recurrence of GVHD on steroid taper while receiving 450 mg of prednisolone per day. In second-line therapy with ATG, etanercept ± mycophenolate mofetil was delivered as previously published. 5 Alemtuzumab was administered at 10 mg s.c. daily for five consecutive days in patients who failed to respond to second-line therapy, as defined by progressive GVHD at any time post ATG/etanercept, no response at 14 days or oCR at 28 days post second-line therapy. Response to alemtuzumab was assessed after 28 days or at the time of death if earlier; CR was defined as resolution of all signs and symptoms of aGVHD (Grade 0) and PR as reduction in severity of GVHD by at least 1 overall grade.
Between August 2007 and October 2009, a total of 13 patients received alemtuzumab as third-line therapy for refractory aGVHD. Overall 2 patients (15%) had grade 3 and 11 patients (85%) had grade 4 GVHD, with the predominant site of involvement being the gastrointestinal tract in 11 patients (85%) and skin in 2 (15%). Overall response rate was 23%, with two CR and one PR observed. However, infectious complications were common, with 12 patients (92%) experiencing at least one clinically significant infectious event. Bacterial infections occurred in 9 patients (69%), with multiple episodes reported in 5 (38%). Viral infections occurred in 8 patients (62%), including CMV reactivation in 6 of 9 CMV seropositive donor and/or recipient pairs, and polyomavirus (BKV) viral cystitis in 2 (15%); note that rates of EBV and/or adenoviral reactivation could not be defined as routine screening for these viruses was not performed. Invasive fungal infection occurred in 4 patients (31%), including confirmed aspergillus infections in 2 patients that contributed to subsequent mortality. Of concern, apparent non-infectious pulmonary toxicity was also common, occurring in 9 patients (69%), including development of diffuse alveolar haemorrhage (DAH) in 2 of 3 patients with alemtuzumab-responding disease (1 CR and 1 PR patient, respectively).
Overall mortality rate was 92%, with only one survivor on long-term follow-up. Median survival was 41 days (range 21-910 days); all deaths occurred within 3 months of alemtuzumab treatment. Causes of death included progressive GVHD in 5 patients (38%), infection in 4 patients (31%) and non-infectious pulmonary toxicity in 3 (23%).
There are an increasing number of reports on the use of alemtuzumab as second-line therapy to treat steroidrefractory aGVHD. [1] [2] [3] [4] 6, 7 However, these reports vary in terms of patient selection as well as alemtuzumab administration, including route of administration, dose and dose schedule, making comparison of results difficult. In general terms, based on relatively small patient numbers, the published data to date suggest that a majority of patients appear to respond to alemtuzumab therapy (overall response rate 50-83%), but CR rates are somewhat lower (20-40%) and OS limited (0-56% of patients). [1] [2] [3] [4] In one report, several patients actually received alemtuzumab as third-line therapy after failing steroids and alternative immunosuppressive agents. Although overall response to alemtuzumab in this subgroup of patients appeared high (overall response rate 71 with 57% PR and 14% CR), survival was more modest (14% overall survival), with significant infection-related mortality noted. Indeed, similar to our experience, even in a second-line setting, the use of alemtuzumab to treat refractory aGVHD is associated with high rates of infectious complications, including from atypical pathogens. However, unlike our experience, previous publications of alemtuzumab therapy in refractory GVHD have not reported significant rates of noninfectious pulmonary toxicity. Whether the pulmonary complications seen in our patient cohort simply reflect the more advanced GVHD status of our patients in comparison with other series, or other undefined factors, is unknown. Given the variable dosing and administration schedules used in the literature, the high rate of infectious complications as well as the high rate of apparent noninfectious pulmonary toxicity seen in our patient cohort, we suggest that if alemtuzumab is to be used in the treatment of refractory aGVHD, a dose-finding study is needed to determine if a balance between efficacy and toxicity of alemtuzumab is achievable for this indication.
In summary, we report our experience of use of alemtuzumab as treatment of steroid and ATG/etanercept-refractory aGVHD. Overall response rate was modest and rates of both infectious and non-infectious toxicity high, resulting in a low rate of long-term survival.
